Please check your internet connection and try again.
# Tab%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520voihep
## Overview
This medication is a combination product containing sofosbuvir and velpatasvir, a direct-acting antiviral (DAA) agent used for the treatment of chronic hepatitis C virus (HCV) infection.
## Primary Indications
Treatment of chronic hepatitis C virus infection. It is approved for all major HCV genotypes (1-6).
## Adult Dosing
**Standard Dose:** One tablet (sofosbuvir 400 mg/velpatasvir 100 mg) taken orally once daily.
## Pediatric Dosing
* **12 years of age and older:** One tablet (sofosbuvir 400 mg/velpatasvir 100 mg) taken orally once daily.
* **For pediatric patients weighing less than 40 kg:** Dosing is based on weight and may involve different formulations or doses. Specific pediatric dosing recommendations should be consulted based on current guidelines and product labeling.
## Dose Adjustments
No dose adjustment is required for mild to moderate hepatic impairment. Avoid use in severe hepatic impairment.
## Contraindications
* Hypersensitivity to the active substances or any of the excipients.
* Concomitant use with strong P-glycoprotein (P-gp) inducers (e.g., rifampin, carbamazepine, phenytoin, St. John's wort).
## Adverse Effects
* **Common:** Headache, fatigue, nausea, insomnia, anemia.
* **Less Common:** Rash, pruritus, arthralgia, myalgia.
* **Serious:** Bradycardia (especially when used with amiodarone), potential for HBV reactivation.
## Key Drug Interactions
* **Strong P-gp inducers:** Avoid concomitant use as they can significantly decrease sofosbuvir and velpatasvir plasma concentrations, leading to reduced efficacy. Examples include rifampin, carbamazepine, phenytoin, and St. John's wort.
* **Amiodarone:** Concomitant use with sofosbuvir/velpatasvir can lead to symptomatic bradycardia. Monitor heart rate closely and consider alternatives if possible.
* **Antacids, H2 Receptor Antagonists, Proton Pump Inhibitors:** May decrease velpatasvir exposure. Separate administration by at least 4 hours (PPIs by at least 12 hours).
## Monitoring
* **HCV RNA levels:** To assess treatment efficacy.
* **Liver function tests:** Baseline and periodically during treatment.
* **Hemoglobin/Hematocrit:** For potential anemia.
* **Heart rate:** If co-administered with amiodarone.
* **HBV DNA:** Consider testing for HBV before initiating treatment, especially in patients with risk factors for HBV infection.
## Clinical Pearls
* This medication is typically given for 12 weeks, but duration may be shorter (e.g., 8 weeks) or longer (e.g., 24 weeks) depending on the HCV genotype, prior treatment history, and presence of cirrhosis. Consult specific treatment guidelines.
* It can be taken with or without food.
* Ensure patients are screened for HBV infection before starting therapy due to the risk of HBV reactivation.
***
**Disclaimer:** This information is intended for healthcare professionals. It is essential to consult the most current prescribing information and relevant clinical guidelines before making any treatment decisions. Dosing and management may vary based on individual patient factors and local protocols.
